MorphoSys Hits Refresh Button On Pipeline With Constellation Buy
Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
You may also be interested in...
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.